Clinical trials: T1 Urinary Bladder Cancer
Bladder Cancer, Ta/T1
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
In this phase 4 trial (000439), subjects with NMIBC CIS (± high-grade Ta/T1) who have not responded to their first dose of nadofaragene firadenovec (commercial ADSTILADRIN received before trial entry) will be offered reinduction…
- Conditions
- Bladder Cancer, Ta/T1, CIS
- Trial name
- ABLE-42 (NCT06390111)
- Testing
- nadofaragene firadenovec
- Where
- 2 sites in United States
- Sponsor
- Ferring Pharmaceuticals